Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 58
Filter
1.
Basic Res Cardiol ; 110(2): 5, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25600224

ABSTRACT

The sustained component of the K(+) outward current in human atrial myocytes is believed to be due to the slowly inactivating ultra-rapid potassium current I Kur and not to the fast inactivating transient outward current Ito. Here we provide evidence for contribution of Ito to this late current due to the effects of dipeptidyl peptidase-like protein (DPP) 10 (DPP10a) interacting with Kv4.3 channels. We studied the late current component of Ito in human atrial myocytes and CHO cells co-expressing Kv4.3 or Kv4.3/KChIP2 (control) and DPP proteins using voltage-clamp technique and a pharmacological approach. A voltage dependent and slowly inactivating late current (43% of peak amplitude) could be observed in atrial myocytes. We found a similar current in CHO cells expressing Kv4.3/KChIP2 + DPP10a, but not in cells co-expressing Kv4.3 + DPP or Kv4.3/KChIP2 + DPP6-S. Assuming that DPP10a influences atrial Ito, we detected DPP10 expression of three alternatively spliced mRNAs, DPP10 protein and colocalization of Kv4.3 and DPP10 proteins in human atrial myocytes. DPP10a did not affect properties of expressed Kv1.5 excluding a contribution to the sustained IKur in atrial cells. To test for the contribution of Kv4-based Ito on sustained K(+) outward currents in human atrial myocytes, we used 4-AP to block IKur, in combination with Heteropoda toxin 2 to block Kv4 channels. We could clearly separate an Ito fraction of about 19% contributing to the late current in atrial myocytes. Thus, the interaction of DPP10a, expressed in human atrium, with Kv4.3 channels generates a sustained current component of Ito, which may affect late repolarization phase of atrial action potentials.


Subject(s)
Action Potentials/physiology , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/metabolism , Myocytes, Cardiac/metabolism , Shal Potassium Channels/metabolism , Aged , Aged, 80 and over , Animals , CHO Cells , Cricetulus , Female , Fluorescent Antibody Technique , Heart Atria/metabolism , Humans , Male , Mice , Middle Aged , Patch-Clamp Techniques , Reverse Transcriptase Polymerase Chain Reaction , Transfection
2.
Br J Pharmacol ; 154(8): 1619-30, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18536759

ABSTRACT

BACKGROUND AND PURPOSE: This study was designed to establish the pathology-specific inhibitory effects of the IKur/Ito/IK,ACh blocker AVE0118 on atrium-selective channels and its corresponding effects on action potential shape and effective refractory period in patients with chronic AF (cAF). EXPERIMENTAL APPROACH: Outward K+-currents of right atrial myocytes and action potentials of atrial trabeculae were measured with whole-cell voltage clamp and microelectrode techniques, respectively. Outward currents were dissected by curve fitting. KEY RESULTS: Four components of outward K+-currents and AF-specific alterations in their properties were identified. Ito was smaller in cAF than in SR, and AVE0118 (10 microM) apparently accelerated its inactivation in both groups without reducing its amplitude. Amplitudes of rapidly and slowly inactivating components of IKur were lower in cAF than in SR. The former was abolished by AVE0118 in both groups, the latter was partially blocked in SR, but not in cAF, even though its inactivation was apparently accelerated in cAF. The large non-inactivating current component was similar in magnitude in both groups, but decreased by AVE0118 only in SR. AVE0118 strongly suppressed AF-related constitutively active IK,ACh and prolonged atrial action potential and effective refractory period exclusively in cAF. CONCLUSIONS AND IMPLICATIONS: In atrial myocytes of cAF patients, we detected reduced function of distinct IKur components that possessed decreased component-specific sensitivity to AVE0118 most likely as a consequence of AF-induced electrical remodelling. Inhibition of profibrillatory constitutively active IK,ACh may lead to pathology-specific efficacy of AVE0118 that is likely to contribute to its ability to convert AF into SR.


Subject(s)
Atrial Fibrillation/drug therapy , Biphenyl Compounds/pharmacology , Potassium Channel Blockers/pharmacology , Potassium Channels/drug effects , Action Potentials/drug effects , Aged , Atrial Fibrillation/physiopathology , Chronic Disease , Electrophysiology , Female , Heart Atria/cytology , Heart Atria/pathology , Humans , In Vitro Techniques , Male , Microelectrodes , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/pathology , Patch-Clamp Techniques , Potassium Channels/metabolism
3.
Naunyn Schmiedebergs Arch Pharmacol ; 378(3): 253-60, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18542927

ABSTRACT

Chronic treatment with cyclosporine A (CyA) is often complicated by severe hypertension. If activation of the beta-adrenergic-receptor-linked adenylyl cyclase (AC) system contributes to hypertension is unresolved. Rats were treated with CyA (20 mg kg(-1) day(-1)) for 7 days. beta-adrenergic, muscarinic, and alpha-adrenergic receptors, G-proteins, and the activity of AC were determined in cardiac and pulmonary plasma membranes. The density of cardiac beta-adrenergic receptors, muscarinic receptors, alpha-adrenergic receptors, G(alphas) and, G(alphai) remained unchanged after treatment with CyA. However, CyA increased the responsiveness of AC to different stimulators. The responsiveness of AC was even more pronounced after solubilization and partial purification, suggesting a direct modulation of the enzyme. These data suggest that CyA modulates the activity of the sympathoadrenergic system by a direct, receptor-independent sensitization of AC, suggesting that this pathway contributes to hypertension in patients treated with CyA.


Subject(s)
Adenylyl Cyclases/metabolism , Cyclosporine/pharmacology , Immunosuppressive Agents/pharmacology , Receptors, Adrenergic, beta/metabolism , Adenylyl Cyclases/biosynthesis , Adenylyl Cyclases/isolation & purification , Adrenergic beta-Agonists/pharmacology , Animals , Arrestin/biosynthesis , Cell Membrane/drug effects , Gene Expression Regulation, Enzymologic/drug effects , Heart/drug effects , In Vitro Techniques , Isoproterenol/pharmacology , Lung/drug effects , Male , Myocardial Contraction/drug effects , Radioligand Assay , Rats , Rats, Inbred WKY , Receptors, G-Protein-Coupled/drug effects , Receptors, Muscarinic/drug effects , beta-Adrenergic Receptor Kinases/biosynthesis
4.
Circulation ; 112(24): 3697-706, 2005 Dec 13.
Article in English | MEDLINE | ID: mdl-16330682

ABSTRACT

BACKGROUND: The molecular mechanism of increased background inward rectifier current (IK1) in atrial fibrillation (AF) is not fully understood. We tested whether constitutively active acetylcholine (ACh)-activated I(K,ACh) contributes to enhanced basal conductance in chronic AF (cAF). METHODS AND RESULTS: Whole-cell and single-channel currents were measured with standard voltage-clamp techniques in atrial myocytes from patients with sinus rhythm (SR) and cAF. The selective I(K,ACh) blocker tertiapin was used for inhibition of I(K,ACh). Whole-cell basal current was larger in cAF than in SR, whereas carbachol (CCh)-activated I(K,ACh) was lower in cAF than in SR. Tertiapin (0.1 to 100 nmol/L) reduced I(K,ACh) in a concentration-dependent manner with greater potency in cAF than in SR (-logIC50: 9.1 versus 8.2; P<0.05). Basal current contained a tertiapin-sensitive component that was larger in cAF than in SR (tertiapin [10 nmol/L]-sensitive current at -100 mV: cAF, -6.7+/-1.2 pA/pF, n=16/5 [myocytes/patients] versus SR, -1.7+/-0.5 pA/pF, n=24/8), suggesting contribution of constitutively active I(K,ACh) to basal current. In single-channel recordings, constitutively active I(K,ACh) was prominent in cAF but not in SR (channel open probability: cAF, 5.4+/-0.7%, n=19/9 versus SR, 0.1+/-0.05%, n=16/9; P<0.05). Moreover, IK1 channel open probability was higher in cAF than in SR (13.4+/-0.4%, n=19/9 versus 11.4+/-0.7%, n=16/9; P<0.05) without changes in other channel characteristics. CONCLUSIONS: Our results demonstrate that larger basal inward rectifier K+ current in cAF consists of increased IK1 activity and constitutively active I(K,ACh). Blockade of I(K,ACh) may represent a new therapeutic target in AF.


Subject(s)
Atrial Fibrillation/etiology , G Protein-Coupled Inwardly-Rectifying Potassium Channels/physiology , GTP-Binding Protein beta Subunits/genetics , Acetylcholine/pharmacology , Aged , Atrial Appendage/cytology , Bee Venoms/pharmacology , Carbachol/pharmacology , Chronic Disease , Electrophysiology , Female , GTP-Binding Protein beta Subunits/physiology , Genotype , Humans , Male , Myocytes, Cardiac/cytology , Myocytes, Cardiac/metabolism , Polymorphism, Single Nucleotide , Potassium/metabolism
5.
Naunyn Schmiedebergs Arch Pharmacol ; 374(3): 249-53, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17106669

ABSTRACT

Activation of both beta(1)- and beta(2)-adrenoceptors increases the contractility of human atrial myocardium through cyclic AMP-dependent pathways. Cyclic AMP is hydrolised by phosphodiesterases, but little is known about which isoenzymes catalyse inotropically relevant cyclic AMP accumulated upon stimulation of beta-adrenoceptor subtypes. We have compared the positive inotropic effects of (-)-noradrenaline and (-)-adrenaline, mediated through beta(1)- and beta(2)-adrenoceptors, respectively, in the absence and presence of the PDE3 inhibitor cilostamide (300 nM) or PDE4 inhibitor rolipram (1 muM) on human atrial trabeculae from non-failing hearts. Cilostamide, but not rolipram, potentiated the effects of both (-)-noradrenaline and (-)-adrenaline. Cilostamide increased the -logEC(50)M of (-)-adrenaline more than of (-)-noradrenaline (P < 0.05), regardless of whether or not the patients had been chronically treated with beta-blockers. The results are consistent with a greater PDE3-catalysed hydrolysis of inotropically relevant cyclic AMP produced through beta(2)-adrenoceptors than beta(1)-adrenoceptors in human atrium.


Subject(s)
Cyclic AMP/metabolism , Phosphodiesterase Inhibitors/pharmacology , Quinolones/pharmacology , Receptors, Adrenergic, beta-1/drug effects , Receptors, Adrenergic, beta-2/drug effects , 3',5'-Cyclic-AMP Phosphodiesterases/metabolism , Adrenergic beta-Antagonists , Aged , Cyclic Nucleotide Phosphodiesterases, Type 3 , Cyclic Nucleotide Phosphodiesterases, Type 4 , Dose-Response Relationship, Drug , Epinephrine/pharmacology , Female , Heart Atria/drug effects , Humans , Hydrolysis , In Vitro Techniques , Male , Middle Aged , Myocardial Contraction/drug effects , Myocardium , Norepinephrine/pharmacology , Receptors, Adrenergic, beta-1/metabolism , Receptors, Adrenergic, beta-2/metabolism , Rolipram/pharmacology
6.
Circulation ; 110(17): 2651-7, 2004 Oct 26.
Article in English | MEDLINE | ID: mdl-15492323

ABSTRACT

BACKGROUND: Although downregulation of L-type Ca2+ current (I(Ca,L)) in chronic atrial fibrillation (AF) is an important determinant of electrical remodeling, the molecular mechanisms are not fully understood. Here, we tested whether reduced I(Ca,L) in AF is associated with alterations in phosphorylation-dependent channel regulation. METHODS AND RESULTS: We used whole-cell voltage-clamp technique and biochemical assays to study regulation and expression of I(Ca,L) in myocytes and atrial tissue from 148 patients with sinus rhythm (SR) and chronic AF. Basal I(Ca,L) at +10 mV was smaller in AF than in SR (-3.8+/-0.3 pA/pF, n=138/37 [myocytes/patients] and -7.6+/-0.4 pA/pF, n=276/86, respectively; P<0.001), though protein levels of the pore-forming alpha1c and regulatory beta2a channel subunits were not different. In both groups, norepinephrine (0.01 to 10 micromol/L) increased I(Ca,L) with a similar maximum effect and comparable potency. Selective blockers of kinases revealed that basal I(Ca,L) was enhanced by Ca2+/calmodulin-dependent protein kinase II in SR but not in AF. Norepinephrine-activated I(Ca,L) was larger with protein kinase C block in SR only, suggesting decreased channel phosphorylation in AF. The type 1 and type 2A phosphatase inhibitor okadaic acid increased basal I(Ca,L) more effectively in AF than in SR, which was compatible with increased type 2A phosphatase but not type 1 phosphatase protein expression and higher phosphatase activity in AF. CONCLUSIONS: In AF, increased protein phosphatase activity contributes to impaired basal I(Ca,L). We propose that protein phosphatases may be potential therapeutic targets for AF treatment.


Subject(s)
Atrial Fibrillation/enzymology , Atrial Fibrillation/physiopathology , Calcium Channels, L-Type/metabolism , Down-Regulation , Phosphoprotein Phosphatases/metabolism , Aged , Chronic Disease , Electric Conductivity , Enzyme Activation , Female , Humans , Isoproterenol/pharmacology , Male , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/enzymology , Myocytes, Cardiac/physiology , Norepinephrine/pharmacology , Patch-Clamp Techniques , Protein Kinases/metabolism
7.
Circulation ; 104(21): 2551-7, 2001 Nov 20.
Article in English | MEDLINE | ID: mdl-11714649

ABSTRACT

BACKGROUND: Clinical and experimental evidence suggest that the parasympathetic nervous system is involved in the pathogenesis of atrial fibrillation (AF). However, it is unclear whether changes in G-protein-coupled inward rectifying K(+) current (I(K,ACh)) contribute to chronic AF. METHODS AND RESULTS: In the present study, we used electrophysiological recordings and competitive reverse-transcription polymerase chain reaction to study changes in I(K,ACh) and the level of the I(K,ACh) GIRK4 subunit in isolated human atrial myocytes and the atrial tissue of 39 patients with sinus rhythm and 24 patients with chronic AF. The density of I(K,ACh) was approximately 50% smaller in myocytes from patients with AF compared with those in sinus rhythm, and this was accompanied by decreased levels of GIRK4 mRNA. The current density of the inward rectifying K(+) current (I(K1)) was 2-fold larger during AF than in sinus rhythm, in correspondence with an increase in Kir2.1 mRNA. The larger I(K1) in AF is consistent with more negative membrane potentials in right atrial trabeculae from AF patients. Moreover, action potential duration was reduced in AF, and the action potential shortening produced by muscarinic receptor stimulation was attenuated, indicating that the changes of I(K1) and I(K,ACh) were functionally relevant. CONCLUSIONS: Chronic human AF induces transcriptionally mediated upregulation of I(K1) but downregulation of I(K,ACh) and attenuates the muscarinic receptor-mediated shortening of atrial action potentials. This suggests that atrial myocytes adapt to a chronically high rate by downregulating I(K,ACh) to counteract the shortening of the atrial effective refractory period due to electrical remodeling.


Subject(s)
Action Potentials , Atrial Fibrillation/genetics , Atrial Fibrillation/physiopathology , Potassium Channels, Inwardly Rectifying/physiology , Potassium Channels/biosynthesis , Receptors, Muscarinic/physiology , Acetylcholine/pharmacology , Action Potentials/drug effects , Aged , Atrial Fibrillation/metabolism , Carbachol/pharmacology , Cells, Cultured , Chronic Disease , Down-Regulation , Electric Conductivity , Female , G Protein-Coupled Inwardly-Rectifying Potassium Channels , Heart Atria/cytology , Heterotrimeric GTP-Binding Proteins/metabolism , Humans , Male , Muscarinic Agonists/pharmacology , Myocardium/cytology , Potassium Channels/genetics , RNA, Messenger/biosynthesis
8.
Am J Surg ; 182(4): 377-83, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11720675

ABSTRACT

BACKGROUND: We have investigated a method, the Kaufman axillary treatment scale (KATS), to help assign patients with a clinically negative axilla to one of three current options of axillary management: standard axillary dissection, sentinel node sampling followed by axillary dissection if the sentinel node is positive, or no axillary surgery at all. The KATS score uses preoperative data to guide the choice of axillary treatment. METHODS: The KATS score is calculated by adding the preoperative values of tumor size, patient age, and pathologic grade. Values range from 1 to 4 for size (1 to 9 mm, 10 to 14 mm, 15 to 19 mm, and 20 to 30 mm), 1 to 3 for age (70 years and over, 50 to 69 years, less than 50 years), and 1 to 2 for grade (low or not low) to calculate the score. The KATS score ranges from 3 to 9. We have applied this score against the SEER (Surveillance, Epidemiology, and End Results) tumor registry of 529 patients with invasive breast cancer with known pathologic data. We then validated it by applying it to our own set of 190 patients using preoperative data. The chi-square test and logistic regression analysis were used for P values (all two sided), univariate and multivariate analysis, odds ratio and confidence intervals utilizing SPSS statistics software. RESULTS: In the SEER database using American Joint Committee on Cancer pathologic size alone, no sizable group was identified with a positive node rate neither below 8% (T1a) nor above 48% (T2). KATS scores of 3 and 4 (68 patients, group 1) identify patients with an average node positive rate of 4.4% (P <0.02, group 1 versus 2). Those patients with KATS scores of 5, 6, and 7 (341 patients, group 2) carry an average node positive rate of 22% (P <0.001, group 2 versus 3). KATS scores of 8 and 9 (120 patients, group 3) identify patients with an average node positive rate of 50% (P <0.001, group 3 versus 1). Similar results were found on our own group of 190 patients using preoperative available data. KATS scores of 3 or 4 (11 patients, group 1) had no positive nodes. Group 2 (100 patients, KATS score 5, 6, and 7) had an average 30% node positive rate. Group 3 (79 patients, KATS score 8 and 9) had 61% node positive rate. The KATS score allows the clinician to separate patients into three axillary management groups. Group 1 are those patients who may need no axillary surgery at all. Group 2 are patients who would benefit from sentinel node mapping. Group 3 has a node positive rate (61%) similar to that of clinically palpable nodes (since not all clinically palpable nodes are positive). Group 3 patients may be considered for standard axillary dissection, similar to the palpable node patient. If group 3 patients have sentinel node mapping, more than half of these patients require axillary dissection and the impact of false negative sentinel node procedures may become clinically significant. CONCLUSIONS: An axillary treatment score has been developed to aid in the triage of patients toward reasonable axillary treatment choices for the benefit of the patient. The KATS score is a guideline and not a mandate. The KATS score attempts to use breakpoints that are both clinically practical and validated by scientific data. Like many other attempts to categorize patients, there is a continuum of data points along any variable. The treating physician utilizing the full array of available data on each patient makes the final clinical decision of axillary management.


Subject(s)
Axilla/surgery , Breast Neoplasms/surgery , Lymph Node Excision , Age Factors , Aged , Axilla/pathology , Databases, Factual , Female , Humans , Lymphatic Metastasis/pathology , Middle Aged , Neoplasm Staging , SEER Program
9.
J Glaucoma ; 2(3): 166-70, 1993.
Article in English | MEDLINE | ID: mdl-19920513

ABSTRACT

Metipranolol is a noncardioselective beta-adrenoceptor antagonist used for more than a decade in Germany as a topical treatment of elevated intraocular pressure. In 1990 +/- 50 cases of anterior uveitis were reported in the United Kingdom. To more fully evaluate the incidence of uveitis, we conducted a large, multicenter, retrospective evaluation of chronic metipranolol use in Germany. We gathered information on 1,306 patients treated with metipranolol from 32 private practices. Approximately one-half of the patients used the 0.3% strength, one-third used the 0.1% strength, and one-sixth used the 0.6% strength. Metipranolol therapy was discontinued in 79 patients (6%). Reasons provided were inadequate efficacy (n = 33), untoward effects (n = 33), and unknown (n = 13). The most frequent untoward effects in these patients were ocular signs and symptoms of either allergy or intolerance and discomfort (n = 18). Newly diagnosed uveitis was observed in five patients (0.4%), none of which required cessation of therapy. Overall, metipranolol was effective and well tolerated. There appears to be a low risk of uveitis associated with the use of metipranolol in Germany, in contrast to the reported experience in the United Kingdom. This difference in experience may be due to the differences in formulation.

10.
Methods Find Exp Clin Pharmacol ; 23(3): 141-4, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11523313

ABSTRACT

In two recent studies immunoadsorption improved left ventricular function in patients with dilated cardiomyopathy (DCM) who were positive for cardiostimulatory autoantibodies against the human beta 1-adrenoceptor (beta 1-AAB). In this study we invasively measured acute hemodynamics during immunoadsorption. Three patients with DCM, who were positive for beta 1-AAB (NYHA-class III, left ventricular ejection fraction < 0.3), were treated with 1 immunoadsorption session daily on 5 consecutive days. Immunoadsorption induced a strong decrease of cardiac index, whereas systemic vascular resistance increased. Baseline levels were reached again several hours after therapy ended. We conclude that during immunoadsorption substantial hemodynamic changes occur in patients positive for beta 1-AAB.


Subject(s)
Autoantibodies/analysis , Cardiomyopathy, Dilated/therapy , Hemodynamics/physiology , Immunoglobulins/therapeutic use , Immunosorbent Techniques , Receptors, Adrenergic, beta-1/immunology , Adult , Aged , Blood Pressure/drug effects , Cardiac Catheterization , Cardiomyopathy, Dilated/diagnostic imaging , Cardiomyopathy, Dilated/immunology , Cardiomyopathy, Dilated/physiopathology , Coronary Circulation/drug effects , Heart Rate/drug effects , Humans , Immunoglobulin G/blood , Pilot Projects , Pulmonary Artery/physiopathology , Time Factors , Ultrasonography , Vascular Resistance/drug effects , Venous Pressure/drug effects , Ventricular Function, Left/drug effects , Ventricular Pressure/drug effects
11.
Ophthalmologe ; 89(6): 455-61, 1992 Dec.
Article in German | MEDLINE | ID: mdl-1362508

ABSTRACT

Metipranolol is a beta-blocker that has been used in ophthalmology and in systemic therapy for about 10 years. Reports about reversible uveitis under the product Glauline (metipranolol-containing eye drops) in England were the reason for extensive studies with metipranolol-containing eye drops produced with different methods. Analytical studies concerning the influence of irradiation sterilization on the drug containers, studies on the toxicity of the ophthalmic drug on tissue cultures, and prospective and retrospective clinical studies on 2,800 glaucoma patients were performed. Irradiation sterilization leads to the formation of free radicals on the surface of the containers and, depending on the radiation dose, to a decrease in the pH of the drug solution. In prospective studies involving 1,516 glaucoma patients, no intraocular side effects due to metipranolol-containing eye drops were found. In the retrospective examination including 1,306 glaucoma patients, 19 cases of uveitis were found. Thirteen cases of recurring iritis were diagnosed, which had already been observed before the onset of glaucoma therapy. In 2 cases the iritis led to secondary glaucoma and was treated with metipranolol. In 2 cases glaucoma was treated with pilocarpine (and dipivefrin) and metipranolol concomitantly. One case of rubeosis iridis was incorrectly classified as iritis. One case is possibly related to metipranolol despite the assessment to the contrary by the ophthalmologist in question. Following the results of these studies, an accumulation of cases of uveitis caused by metipranolol can be excluded.


Subject(s)
Glaucoma/drug therapy , Metipranolol/adverse effects , Uveitis, Anterior/chemically induced , Adolescent , Adult , Aged , Aged, 80 and over , Child , Drug Monitoring , Female , Humans , Male , Metipranolol/administration & dosage , Middle Aged , Ophthalmic Solutions , Product Surveillance, Postmarketing , Retrospective Studies
12.
Percept Mot Skills ; 60(2): 487-94, 1985 Apr.
Article in English | MEDLINE | ID: mdl-4000866

ABSTRACT

Flicker fusion frequencies of 48 healthy controls and of 35 alcoholics were measured to detect possible associations between flicker fusion and signs of nonspecific brain damage, the aim of the study. FFF was statistically significantly lower in patients addicted to alcohol than in healthy subjects. Lower flicker fusion frequencies were associated with the severeness of organic psychosis as rated psychopathologically. The hypothesis that addiction to alcohol is a sign of diffuse, nonspecific, organic brain damage was discussed.


Subject(s)
Alcoholism/psychology , Flicker Fusion/drug effects , Neurocognitive Disorders/psychology , Adult , Alcoholism/complications , Ethanol/adverse effects , Female , Humans , Male , Neurocognitive Disorders/etiology , Substance-Related Disorders/psychology
13.
Angew Chem Int Ed Engl ; 38(24): 3752-3756, 1999 Dec 16.
Article in English | MEDLINE | ID: mdl-10649347

ABSTRACT

The differences in the fluorescence behavior of a polyphenylene dendrimer with eight peryleneimides chromophores (1) and a single hexaphenylperyleneimide chromophore have been investigated at a single-molecule level through the combination of ultrasensitive fluorescence detection and microscopy.

14.
Herzschrittmacherther Elektrophysiol ; 21(4): 217-21, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21082185

ABSTRACT

Atrial fibrillation (AF) is accompanied by a high risk of thromboembolic complications necessitating anticoagulation therapy. Arrhythmias have a high tendency to become persistent. Catheter ablation techniques are highly effective in the treatment of AF; however, these procedures are far too costly and time-consuming for the routine treatment of large numbers of AF patients. Moreover, many patients prefer drug treatment although conventional antiarrhythmic drugs are moderately effective and are burdened with severe cardiac and noncardiac side effects. New antifibrillatory drugs developed for the treatment of AF include multichannel blockers with a high degree of atrial selectivity. The rationale of this approach is to induce antiarrhythmic actions only in the atria without conferring proarrhythmic effects in the ventricles.Atrial selective drug action is expected with ion channel blockers targeting ion channels that are expressed predominantly in the atria, i.e., Kv1.5 (I(Kur)), or Kir 3.1 and Kir 3.4 (I(K,ACh)). Na(+) channel blockers that dissociate rapidly may exert atrial selectivity because of subtle differences in atrial and ventricular action potentials. Finally, atrial-selective targets may evolve due to disease-specific processes (e.g., rate-dependent Na(+) channel blockers, selective drugs against constitutively active I(K,ACh) channels).


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/drug therapy , Heart Atria/drug effects , Acetylcholine/physiology , Anti-Arrhythmia Agents/adverse effects , Atrial Fibrillation/complications , Catheter Ablation , Drug-Related Side Effects and Adverse Reactions , Electrocardiography/drug effects , Heart Ventricles/drug effects , Humans , Potassium Channels/drug effects , Sodium Channels/drug effects , Thromboembolism/prevention & control
17.
Phys Rev Lett ; 103(13): 132301, 2009 Sep 25.
Article in English | MEDLINE | ID: mdl-19905504

ABSTRACT

We report first results on a deep subthreshold production of the doubly strange hyperon Xi;{-} in a heavy-ion reaction. At a beam energy of 1.76A GeV the reaction Ar + KCl was studied with the High Acceptance Di-Electron Spectrometer at SIS18/GSI. A high-statistics and high-purity Lambda sample was collected, allowing for the investigation of the decay channel Xi;{-} --> Lambdapi;{-}. The deduced Xi;{-}/(Lambda + Sigma;{0}) production ratio of (5.6 +/- 1.2_{-1.7};{+1.8}) x 10;{-3} is significantly larger than available model predictions.

18.
Phys Rev Lett ; 98(5): 052302, 2007 Feb 02.
Article in English | MEDLINE | ID: mdl-17358850

ABSTRACT

The invariant-mass spectrum of e+e- pairs produced in 12C+12C collisions at an incident energy of 2 GeV per nucleon has been measured for the first time. The measured pair production probabilities span over 5 orders of magnitude from the pi(0)-Dalitz to the rho/omega invariant-mass region. Dalitz decays of pi(0) and eta account for all the yield up to 0.15 GeV/c(2), but for only about 50% above this mass. A comparison with model calculations shows that the excess pair yield is likely due to baryon-resonance and vector-meson decays. Transport calculations based on vacuum spectral functions fail, however, to describe the entire mass region.

20.
Br J Anaesth ; 95(3): 300-4, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15964889

ABSTRACT

BACKGROUND: Third-year students in the Dresden Medical School Programme undergo a 6 week course 'Basics of Drug Therapy' in a problem-based learning curriculum. As part of this course a practical seminar about antiarrhythmic drugs and ECG was set up. This study was conducted to evaluate the use of a simulator in this course. METHODS: A total of 234 students were randomly allocated to receive instructions with (Group S) or without (Group C [control]) the use of a simulator. After a lecture on antiarrhythmic drugs, arrhythmias were presented to Group S using an advanced life support (ALS) manikin. The students were asked to administer a drug or to defibrillate, and the outcome was shown on the monitor. The students in Group C were presented with ECG charts without a simulator. The course was evaluated by a questionnaire and multiple-choice questions (MCQ) about arrhythmias. RESULTS: We received 222 questionnaires. The content-time ratio was rated almost perfect in both groups, but the students in Group S rated the course better suited to link theory and practice. Students in Group S considered the simulator helpful and a good tool for teaching, and the extra effort to be worthwhile. A significantly higher number of students in Group S preferred electric cardioversion as therapy for ventricular tachycardia. CONCLUSIONS: An ALS manikin can be an effective tool in teaching clinical pharmacology.


Subject(s)
Anesthesiology/education , Anti-Arrhythmia Agents/therapeutic use , Education, Medical, Undergraduate/methods , Electrocardiography , Teaching/methods , Adult , Consumer Behavior , Emergency Medicine/education , Female , Germany , Humans , Male , Manikins , Patient Simulation , Students, Medical/psychology
SELECTION OF CITATIONS
SEARCH DETAIL